Inovio Pharmaceuticals, Inc. (INO)
| Previous close | 2.4600 |
| Open | 2.5300 |
| Bid | 2.6000 x 1800 |
| Ask | 2.6100 x 1200 |
| Day's range | 2.4650 - 2.6350 |
| 52-week range | 1.3800 - 9.7400 |
| Volume | |
| Avg. volume | 6,980,819 |
| Market cap | 648.44M |
| Beta (5Y monthly) | 0.88 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.5420 |
| Earnings date | 07 Nov 2022 - 11 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.20 |
- Motley Fool
Why Inovio Pharmaceuticals Is Gaining Today
Inovio Pharmaceuticals' (NASDAQ: INO) stock rose by more than 18.5% as of 2:30 p.m. ET on Wednesday after the company's Q2 earnings results broke the news of its plans to restructure its operations to conserve cash. The biotech will lay off 18% of its full-time employees while additionally reducing its contractor head count by a massive 86%. Inovio also announced the appointment of a new chief medical officer, Dr. Michael Sumner, which might be another contributing factor to the gain of its stock today.
- Motley Fool
Inovio Pharmaceuticals (INO) Q2 2022 Earnings Call Transcript
Good afternoon, and thank you for joining the Inovio second quarter 2022 financial results conference call. Joining me today on today's call are Dr. Jacque Shea, president and CEO; Mr. Peter Kies, chief financial officer; Dr.
- Zacks
Inovio Pharmaceuticals (INO) Reports Q2 Loss, Tops Revenue Estimates
Inovio (INO) delivered earnings and revenue surprises of -53.33% and 264.65%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
